Neovasc (NVCN) has an average broker rating of 2, which is interpreted as a Buy, as rated by 2 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Neovasc (NVCN) stock is expected to deviate a maximum of $1.41 from the average target price of $11 for the short term period. 2 Street Experts have initiated coverage on the stock with the most promising target being $12 and the most muted being $10.
For the current week, the company shares have a recommendation consensus of Buy. Also, Major Brokerage house, Ladenburg Thalmann downgrades its ratings on Neovasc (NASDAQ:NVCN). According to the latest information available, the shares are now rated Neutral by the analysts at the agency. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on May 20, 2016.
Neovasc (NASDAQ:NVCN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.55 and $0.54 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.79. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.77, notching a gain of 40.64% for the day. The total traded volume was 9,726,229 . The stock had closed at $0.55 on the previous day.
Neovasc Inc. is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Reducer for the treatment of refractory angina and a line of advanced biological tissue products that are used as key components in third-party medical products, including transcatheter heart valves. Its Tiara is a product for treating mitral valve disease. The Tiara is in preclinical/early clinical stage development to provide an invasive transcatheter device. The Tiara valve is made up of two components: the leaflets and skirt. It produces Peripatch, a biological tissue product that is manufactured from pericardium, which is the protective sac that surrounds the heart of an animal. It provides product development and specialized manufacturing services related to Peripatch tissue-based products.